Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Metab Brain Dis ; 37(7): 2603-2613, 2022 10.
Article in English | MEDLINE | ID: mdl-35922733

ABSTRACT

Multiple sclerosis (MS) is a chronic autoimmune disorder of central nervous system which is increasing worldwide. Although immunosuppressive agents are used for the treatment of MS disease, nevertheless the lack of non-toxic and efficient therapeutic method is perceptible. Hence, this study aims to evaluate the effect of Contactin-associated protein (Caspr) antibody-, poly ethylene glycol (PEG)- and exosome combined gold nanoparticles (GNPs) in comparison to Glatiramer acetate as a selective treatment of MS disease in the experimental autoimmune encephalomyelitis (EAE) mouse model. EAE was induced in female C57BL/6 mice and 25-day treatment with anti-Caspr-, PEG- and exosome combined GNPs was evaluated. Histopathological examination of spinal cord, regulatory T cells as well as inflammatory pathway including IFN-É£ and IL-17 and mir-326 were investigated. The results showed the severity of MS symptoms was significantly decreased in all treated groups. Histological examination of the spinal cord indicated the reduced demyelination and immune cell infiltration. Besides, regulatory T cells were significantly increased following all treatments. Remarkably, the cytokine levels of IFN-É£ and IL-17 as well as mir-326 is altered in treated groups. Taken together, the obtained findings demonstrate that the administration of anti-Caspr-, PEG- and exosome combined GNPs can be considered a potential treatment in MS disease.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental , Metal Nanoparticles , Multiple Sclerosis , Animals , Female , Mice , Contactins , Cytokines/metabolism , Disease Models, Animal , Ethylene Glycols , Glatiramer Acetate/pharmacology , Glatiramer Acetate/therapeutic use , Gold , Immunosuppressive Agents/pharmacology , Immunosuppressive Agents/therapeutic use , Interleukin-17 , Metal Nanoparticles/therapeutic use , Mice, Inbred C57BL , Multiple Sclerosis/drug therapy , Multiple Sclerosis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...